Genes, Culture, and Medicines: Bridging Gaps in Treatment for Hispanic Americans
This report brings together for the first time a growing body of scientific research demonstrating substantial disparities in pharmaceutical therapy for Hispanic Americans. These disparities in pharmaceutical treatment are substantial and often persist even after adjustment for differences in income, age, insurance coverage, and coexisting medical conditions. Emerging research demonstrates that genetic variations affect Hispanic Americans and may require dosage adjustments to achieve an optimal therapeutic effect.
Test Blog Post
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Fusce luctus arcu sed erat malesuada tincidunt. Ut commodo ante et tortor egestas nec...
Taking Patient Variations Into Account
Dr. Lisa Egbuonu-Davis, founder of ROI Squared, explains that data is generally designed toward looking at the mean differences instead of the...Understanding Individual Patients' Health Care Needs
Paul Martino, SVP of Clinical Strategy and Innovation at WellPoint, Inc., explains that it's important for payers and other health care stakeholders...Payer Views of Individualized Health Care
Dr. Daniel Malone, professor at the University of Arizona School of Pharmacy, explains how payers view the issue of individualized therapy. He says...
Pharmaceuticals Play Key Role in Achieving ACO Quality, Cost Goals
WASHINGTON, DC, July 18, 2012–As health care providers set up accountable care organizations (ACOs) and other value-based care programs,...NPC, Health Industry Forum, AHIP and Blue Cross Blue Shield to Host Symposium, Shaping Convergent Strategies for Comparative Effectiveness Research
Washington, DC (June 21, 2010)—Dr. Janet Woodcock, director of the Center for Drug Evaluation and Research at the Food and Drug Administration, Dr....Avalere Explores Impact of Comparative Effectiveness Research on Healthcare Innovation
Washington, DC (November 17, 2009) – A new Avalere Health report presents an analytic framework for evaluating the impact of comparative...Leaders in Healthcare to Examine Impact of Comparative Effectiveness Research on Personalized Medicine
Arlington, VA (October 27, 2009)—As Congress continues its efforts to reform the health care system, the National Pharmaceutical Council (NPC) and...
Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?
A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...Framework Helps ACOs Leverage Pharmaceuticals to Realize Quality, Cost Goals
Medications are more than an item on the balance sheet for health care providers. Pharmaceuticals offer a route to manage costs while achieving...Comparative Effectiveness Research and the Changing Health Care Landscape
This content appeared in the January 2, 2012 print edition of Chain Drug Review. In the span of just one year, the health care landscape has...CER: Who Can Say What, and When Can They Say It?
With billions of dollars in comparative effectiveness research (CER) set for completion in coming years, there will be broader discussions about the...Understanding Individual Patients' Health Care Needs
Paul Martino, SVP of Clinical Strategy and Innovation at WellPoint, Inc., explains that it's important for payers and other health care stakeholders...Taking Patient Variations Into Account
Dr. Lisa Egbuonu-Davis, founder of ROI Squared, explains that data is generally designed toward looking at the mean differences instead of the...Payer Views of Individualized Health Care
Dr. Daniel Malone, professor at the University of Arizona School of Pharmacy, explains how payers view the issue of individualized therapy. He says...Dr. Puckrein on the Issue of Individual Patient Differences
Dr. Gary Puckrein, founder and president of the National Minority Quality Forum, says that there is tremendous variability in how different patients...Test Blog Post
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Fusce luctus arcu sed erat malesuada tincidunt. Ut commodo ante et tortor egestas nec...Individual Treatment Effects: From Research to Action
During the next few years, a substantial number of comparative effectiveness research (CER) studies will examine a treatment’s effect on the average...Research Methods 101: Will Individual Treatment Effects Be Considered?
In the last post of this month’s series on research methods, we wanted to touch upon an important aspect of comparative effectiveness research: what...Research
Component Management Fails to Save Health Care System Costs: The Case of Restrictive Formularies
The general failure of formularies and other limitat
Pain: Current Understanding of Assessment, Management, and Treatments
Pain is the most common reason individuals seek heal
Pharmaceuticals for Elders: Why Innovation Matters
The current policy debate over drug-benefit reform a
- 1 of 36
- >
Commentary & Testimony
Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?
Framework Helps ACOs Leverage Pharmaceuticals to Realize Quality, Cost Goals
Comparative Effectiveness Research and the Changing Health Care Landscape
CER: Who Can Say What, and When Can They Say It?
Medicare Part D, Adherence, and the Value of Pharmaceuticals